Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 133.49B |
| Revenue (ttm) | 28.24B |
| Net Income (ttm) | 478.00M |
| Shares Out | 345.66M |
| EPS (ttm) | 1.37 |
| PE Ratio | 281.90 |
| Forward PE | 23.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 315,212 |
| Average Volume | 555,533 |
| Open | 382.40 |
| Previous Close | 382.40 |
| Day's Range | 380.20 - 389.00 |
| 52-Week Range | 241.80 - 432.80 |
| Beta | 0.18 |
| RSI | 50.03 |
| Earnings Date | Feb 5, 2026 |
About STO:SOBI
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy... [Read more]
Full Company ProfileFinancial Performance
In 2025, STO:SOBI's revenue was 28.24 billion, an increase of 8.50% compared to the previous year's 26.03 billion. Earnings were 478.00 million, a decrease of -87.70%.
Financial StatementsNews
Swedish Orphan Biovitrum AB (publ) (SWOBY) Analyst/Investor Day Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) Analyst/Investor Day Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q4 2025 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q4 2025 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) M&A Call Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) M&A Call Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q3 2025 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:SWOBY) Q3 2025 Earnings Call October 20, 2025 7:00 AM EDT Company Participants Guido Oelkers - CEO & President Henrik Stenqvist - Chief Financial Officer Lydi...
Swedish Orphan Biovitrum AB (publ) - Special Call
Swedish Orphan Biovitrum AB (publ) - Special Call Company Participants Guido Oelkers - CEO & President Matthew Winfield Conference Call Participants Herbert S. B. Baraf Rehan Azeem Gonzalo Artiach Cas...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2025 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q2 2025 Earnings Conference Call July 16, 2025 8:00 AM ET Company Participants Guido Oelkers - CEO & President Henrik Stenqvist - Chief Financial Offic...
Swedish Orphan Biovitrum: Haematology Focus Seems To Be Paying Off
BIOVF is moving from legacy products to a six-asset strategic portfolio that's mostly centered on Haematology. In particular, its Haematology segment contributed 71.6% of BIOVF's Q1 revenues, and five...
Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Transcript
Swedish Orphan Biovitrum AB (OTCPK:BIOVF) Q1 2025 Earnings Conference Call April 29, 2025 9:30 AM ET Company Participants Guido Oelkers - CEO Henrik Stenqvist - CFO Lydia Abad-Franch - Head, R&D and C...
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , April 1, 2025 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be ...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2024 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q4 2024 Earnings Conference Call February 5, 2025 8:30 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Fina...
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"),...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2024 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Guido Oelkers - CEO Henrik Stenqvist - CFO Lydia Abad-Franch - Head, ...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2024 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q2 2024 Earnings Conference Call July 16, 2024 8:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financi...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2023 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2023 Earnings Call Transcript
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , Nov. 30, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) ("Sobi") has, as previously announced, carried out a share issue of series C shares, which has resulted...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2023 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2023 Earnings Call Transcript
Bulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting (EGM)
STOCKHOLM, Sweden , Aug. 15, 2023 /PRNewswire/ -- The Sobi® EGM was convened today on 15 August 2023. At the EGM, the shareholders, in accordance with the proposed resolutions, resolved as follows: Au...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2023 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q2 2023 Results Conference Call July 18, 2023 7:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financia...
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , June 30, 2023 /PRNewswire/ -- As per 30 June 2023, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 311,336,796 shares. All shares are common shares.
Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing
XTEND-Kids data confirms the efficacy and safety profile of efanesoctocog alfa with 50 IU/kg dosing in previously treated children as already shown in adults and adolescents. Factor VIII inhibitor dev...
CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.
Swedish Orphan Biovitrum will buy CTI for $9.10 a share as it looks to expand its rare hematology portfolio.
CTI BioPharma soars on deal news, while Upstart and Rivian climb after earnings
CTI BioPharma Corp. CTIC stock soared 83% in premarket trading after Swedish Orphan Biovitrum AB SE:SOBI said it had entered into an agreement to acquire the biotech in a deal valued at $1.7 billion. ...